Blockbusters like Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate, formerly known as X842, takes a new approach to provide improved management of esophagitis and GERD symptoms. 

Today's GERD medication has significant shortcomings

De-risked development program – phase II study in planning

Linaprazan glurate provides improved
acid control

18.5 million

people in initial, niche target population


individuals exposed to the active metabolite of

linaprazan glurate

in clinical trials

Team with experience from development of Losec and Nexium